tirzepatide atrial fibrillation Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

25.44

★★★★☆4.8 (126)

Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials

24.48

★★★★★4.9 (98)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

20.83

★★★★★5.0 (157)

What is the appropriate micro‑dosing (titration) regimen of tirzepatide for a 68‑year‑old obese male with prior atrial‑fibrillation ablations, a permanent pacemaker, a Watchman device, chronic obstructive pulmonary disease, and chronic heart failure?

20.01

★★★★★4.7 (84)

Epicardial Adipose Tissue as a Cardiometabolic Target in Atrial Fibrillation: Implications for Ablation Strategies and Emerging Metabolic Therapies

29.05

★★★★★4.9 (203)

Tirzepatide Improved Outcomes in Patients with Both Atrial Fibrillation and COPD: Study

23.38

★★★★★5.0 (176)

Evidence that tirzepatide protects against diabetes-related cardiac damages | Cardiovascular Diabetology

20.25

★★★★★4.8 (132)